MannKind/$MNKD

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About MannKind

MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.

Ticker

$MNKD
Primary listing

Industry

Biotechnology

Employees

405

ISIN

US56400P7069

MannKind Metrics

BasicAdvanced
$1.2B
36.83
$0.10
1.14
-

What the Analysts think about MannKind

Analyst ratings (Buy, Hold, Sell) for MannKind stock.

Bulls say / Bears say

MannKind Corporation significantly reduced its debt by $194 million through the exchange of convertible notes for stock and cash, enhancing its financial stability and reducing annual interest expenses by $4.9 million. (kark.com)
Analysts have shown increased confidence in MannKind, with StockNews.com upgrading the stock to a 'buy' rating in March 2025, reflecting positive sentiment towards the company's prospects. (defenseworld.net)
MannKind reported a non-GAAP adjusted net income of $21.6 million for Q1 2025, indicating strong financial performance and operational efficiency. (stocktitan.net)
Insider selling activity, including the sale of 55,000 shares by insider Stuart A. Tross in November 2024, may raise concerns about internal confidence in the company's future performance. (etfdailynews.com)
Despite positive analyst ratings, the stock's price target was increased by only 8.21% to $7.40 in October 2023, suggesting limited upside potential in the near term. (nasdaq.com)
The company's high P/E ratio of 97.14 as of December 2024 indicates that the stock may be overvalued relative to its earnings, potentially deterring value-focused investors. (americanbankingnews.com)
Data summarised monthly by Lightyear AI. Last updated on 10 Jul 2025.

MannKind Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

MannKind Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $MNKD

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs